Herbst Kinsky has advised Hookipa Biotech AG during its raising of EUR 10 million in an extended series B financing with existing investors Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures, and BioMedPartners.
Herbst Kinsky describes Hookipa Biotech AG as "an exciting early stage biotech company," and reports that it is developing "a new class of innovative immunotherapeutics and vaccines based on its proprietary Vaxwave and TheraT technologies."
The Herbst Kinsky team was led by Partner Philipp Kinsky, who commented, “We are very pleased to be part of the success story. We would like to congratulate our long-lasting client Hookipa on this next milestone."
Kinsky was supported by Herbst Kinsky Associates David Pachernegg and Florian Pollak.
